abbrevi
ebv
epsteinbarr
viru
ha
hemagglutinin
hpai
highli
pathogen
avian
influenza
virus
ig
immunoglobulin
intranas
ly
ip
intraperiton
ly
mab
monoclon
antibodi
pbmc
peripher
blood
mononuclear
cell
tcid
tissu
cultur
infecti
dose
wt
wild
type
correspond
address
email
lanzavecchia
irb
unisich
al
ksubbarao
niaidnihgov
ks
author
contribut
equal
work
background
new
prophylact
therapeut
strategi
combat
human
infect
highli
pathogen
avian
influenza
hpai
virus
need
gener
neutral
human
monoclon
antibodi
mab
test
efficaci
prophylaxi
therapi
murin
model
infect
use
epsteinbarr
viru
immort
memori
b
cell
vietnames
adult
recov
infect
hpai
virus
supernat
b
cell
line
screen
viru
neutral
assay
b
cell
line
secret
neutral
antibodi
clone
mab
purifi
crossreact
antibodi
differ
strain
test
vitro
neutral
assay
prophylact
therapeut
efficaci
vivo
test
mice
vitro
mab
neutral
clade
clade
ii
virus
whilst
neutral
clade
virus
vivo
confer
protect
lethal
mice
challeng
dosedepend
manner
mab
prophylaxi
provid
statist
signific
reduct
pulmonari
viru
titer
reduc
associ
inflamm
lung
restrict
extrapulmonari
dissemin
viru
therapeut
dose
provid
robust
protect
lethal
least
h
postinfect
mab
also
therapeut
activ
vivo
clade
ii
viru
studi
provid
proof
concept
fulli
human
mab
neutral
activ
rapidli
gener
peripher
blood
convalesc
patient
mab
effect
prevent
treatment
infect
mous
model
panel
neutral
crossreact
mab
might
use
prophylaxi
adjunct
treatment
human
case
influenza
continu
circul
highli
pathogen
avian
influenza
hpai
strain
subtyp
occasion
coincid
case
human
infect
patient
februari
fatal
trigger
intern
public
health
concern
basi
haemagglutinin
ha
sequenc
circul
hpai
virus
fall
differ
lineag
term
clade
virus
isol
viet
nam
indonesia
respect
design
refer
strain
clade
ii
ha
sequenc
clade
clade
ii
virus
differ
amino
acid
level
virus
two
clade
antigen
distinguish
virus
effici
transmit
person
person
potenti
viru
capabl
effici
humantohuman
transmiss
could
result
either
adapt
hpai
virus
andor
reassort
viru
genom
circul
human
influenza
viru
widespread
dissemin
viru
could
caus
signific
morbid
mortal
sinc
human
gener
immunolog
influenza
subtyp
human
overal
mortal
hpai
infect
exce
variat
accord
patient
age
year
infect
basi
appar
virul
hpai
strain
human
rel
poorli
understood
vietnames
patient
diseas
character
sever
pneumonia
lymphopenia
high
viral
load
respiratori
tract
hypercytokinemia
beyond
support
care
treatment
option
human
patient
avian
influenza
remain
limit
empir
virus
resist
older
antivir
agent
amantadin
rimantadin
clinic
efficaci
neuraminidas
inhibitor
oseltamavir
zanamavir
yet
confirm
prospect
studi
addit
virus
resist
oseltamavir
report
patient
recov
infect
possess
antibodi
neutral
infect
viru
vitro
suggest
antibodymedi
immun
may
contribut
resolut
infect
antibodybas
therapi
human
patient
hitherto
unexplor
potenti
viabl
treatment
option
clinic
antibodi
therapi
use
polyclon
monoclon
antibodi
mab
effect
use
prophylaxi
varicella
hepat
hepat
b
rabi
respiratori
syncyti
viru
infect
context
influenza
specif
mab
confer
prophylact
therapeut
protect
mice
passiv
immun
vertic
acquisit
specif
antibodi
also
associ
influenza
immun
anim
model
earli
infanc
human
immedi
relev
transfus
human
blood
product
patient
recov
spanish
flu
associ
reduct
influenza
mortal
pandem
human
mous
mab
equin
f
fragment
specif
also
use
efficaci
prophylaxi
therapi
mous
model
collect
observ
suggest
passiv
antibodi
therapi
hpai
virus
could
potenti
viabl
adjunct
treatment
option
human
case
influenza
one
approach
gener
virusspecif
neutral
mab
use
highli
effici
method
epsteinbarr
ebv
mediat
immort
memori
b
cell
convalesc
individu
approach
rapid
yield
stabl
b
cell
clone
secret
fulli
human
antibodi
select
cours
immun
respons
pathogen
aim
studi
gener
human
mab
neutral
activ
virus
mab
deriv
immort
memori
b
cell
collect
donor
recov
infect
four
mab
neutral
activ
vitro
prophylact
therapeut
efficaci
mice
challeng
hpai
mab
other
like
could
role
adjunct
treatment
human
case
influenza
four
adult
blood
donor
studi
diagnos
hpai
infect
januari
februari
hospit
tropic
diseas
ho
chi
minh
citi
viet
nam
diagnosi
hpai
influenza
infect
made
rtpcr
respiratori
specimen
four
donor
cultur
influenza
respiratori
specimen
donor
clinic
featur
acut
diseas
three
four
patient
donor
describ
previous
patient
onlin
supplement
screen
supernat
b
cell
line
clone
perform
microneutr
assay
use
mdck
cell
tcid
tissu
cultur
infecti
dose
essenti
describ
previous
briefli
neat
supernat
incub
tcid
viru
h
room
temperatur
prior
addit
monolay
mdck
cell
cell
monolay
incub
examin
cytopath
effect
determin
endpoint
neutral
antibodi
titer
perform
similar
fashion
except
plasma
supernat
sampl
serial
twofold
dilut
prior
mix
tcid
viru
plasma
sampl
test
start
dilut
supernat
test
start
dilut
residu
infect
test
four
well
per
dilut
neutral
titer
defin
reciproc
highest
dilut
serum
infect
tcid
appropri
wildtyp
wt
viru
mdck
cell
complet
neutral
well
infect
identifi
presenc
cytopath
effect
titer
calcul
reedmuench
method
frozen
peripher
blood
mononuclear
cell
pbmc
thaw
stain
directli
label
antibodi
pharmingen
http
wwwbdbiosciencescomhom
immunoglobulin
ig
igd
iga
jackson
immunoresearch
http
wwwjacksonimmunocom
b
cell
isol
use
facsaria
becton
dickinson
http
wwwbdcom
immort
b
cellswel
replic
cultur
use
ebv
presenc
cpg
oligodeoxynucleotid
mycrosynth
http
www
microsynthch
irradi
allogen
pbmc
previous
describ
cell
cultur
complet
rpmi
supplement
fetal
calf
serum
hyclon
laboratori
http
wwwhyclonecom
cultur
supernat
harvest
day
assay
neutral
activ
tcid
influenza
cultur
measur
neutral
activ
clone
cellwel
presenc
cpg
irradi
pbmc
b
cell
clone
cultur
high
cell
densiti
complet
rpmi
igdeplet
fetal
calf
serum
produc
enrich
supernat
contain
mg
mabsml
mab
also
purifi
protein
g
column
ge
healthcar
europ
http
wwwgehealthcarecom
isotyp
subclass
light
chain
mab
character
elisa
use
specif
antibodi
hrplabel
antihuman
ig
antibodi
southern
biotechnolog
http
www
southernbiotechcom
antibodi
quantifi
refer
standard
certifi
prepar
sigmaaldrich
http
wwwsigmaaldrichcom
group
femal
balbc
mice
wk
old
mean
weight
g
use
experi
inocul
mice
tissu
harvest
perform
biosafeti
cabinet
personnel
wear
power
air
purifi
respir
influenzainfect
anim
hous
usda
cdc
accredit
biosafeti
level
anim
facil
accord
protocol
approv
nih
anim
care
use
committe
measur
prophylact
efficaci
mice
intraperiton
ip
inject
ml
variou
antibodi
prepar
hyperimmun
sheep
antisera
rais
baculoviru
express
ha
kindli
provid
dr
g
kembl
medimmun
vaccin
http
wwwmedimmunecom
mab
administ
either
purifi
igg
enrich
cultur
supernat
control
human
antibodi
mab
specif
diphtheria
toxin
anthrax
protect
antigen
respect
prepar
fashion
influenzareact
antibodi
twentyfour
hour
ip
administr
mice
bled
collect
sampl
measur
neutral
human
mab
titer
challeng
intranas
tcid
avietnam
mice
observ
weigh
daili
viral
infect
determin
viral
titer
follow
challeng
mice
kill
lung
brain
spleen
asept
remov
tissu
homogen
leibovitz
medium
invitrogen
http
wwwinvitrogencom
supplement
antibioticantimycot
solut
gibco
http
wwwinvitrogencom
achiev
suspens
lung
w
v
spleen
wv
brain
wv
titrat
monolay
mdck
cell
quadrupl
viral
titer
calcul
reed
muench
method
express
log
tcid
per
gram
tissu
therapi
mice
first
infect
ld
h
later
inject
ip
ml
mab
prepar
therapi
mice
first
infect
ld
h
later
inject
ip
ml
mab
prepar
mice
necropsi
lung
inflat
neutral
buffer
formalin
embed
paraffin
section
prepar
slide
stain
hematoxylin
eosin
immunohistochem
demonstr
antigen
paraffin
section
prepar
abc
immunohistochemistri
perform
use
goat
antibodi
avian
influenza
goat
alpha
niaid
refer
reagent
bei
resourc
http
wwwbeiresourcesorg
dilut
vector
rabbit
antigoat
secondari
antibodi
vector
abc
elit
label
vector
laboratori
http
www
vectorlabscom
diaminobenzidin
chromogen
hematoxylin
counterstain
lung
patholog
evalu
semiquantit
manner
pathologist
jw
blind
treatment
kaplanmei
surviv
curv
log
rank
test
use
measur
differ
treatment
arm
prophylact
therapeut
treat
mice
mannwhitney
u
test
use
measur
differ
viral
load
mous
tissu
statist
purpos
sampl
undetect
viral
burden
given
valu
log
tcidg
analys
perform
stata
softwar
statacorp
http
wwwstatacom
blood
sampl
four
vietnames
adult
recov
hpai
infect
collect
mo
postinfect
igg
memori
b
cell
recov
frozen
pbmc
immort
ebv
cultur
secret
neutral
antibodi
identifi
microneutr
assay
prototyp
clade
viru
clone
limit
dilut
supernat
approxim
well
screen
identifi
independ
clone
secret
neutral
antibodi
clone
three
isol
donor
one
donor
eleven
donor
number
clone
isol
donor
correl
plasma
titer
neutral
antibodi
though
surpris
given
small
sampl
size
clone
produc
antibodi
recogn
ha
elisa
neutral
live
viru
also
identifi
donor
unpublish
data
clone
isol
donor
first
obtain
studi
extens
subsequ
clone
tabl
contrast
none
clone
neutral
influenza
viru
tabl
j
mab
irrelev
specif
diphtheria
toxin
anthrax
protect
antigen
use
neg
control
neutral
influenza
viru
tabl
thu
mab
select
studi
demonstr
broad
vitro
neutral
activ
virus
isol
albeit
variat
potenc
balbc
mice
highli
suscept
infect
hpai
virus
isol
asia
sinc
follow
administr
virus
replic
high
titer
lung
mice
isol
dissemin
extrapulmonari
site
lethal
mice
explor
efficaci
mab
preexposur
prophylaxi
balbc
mice
passiv
immun
ip
administr
grade
dose
mab
challeng
h
later
prepar
mab
confer
protect
lethal
p
figur
mab
also
confer
protect
lethal
infect
lower
efficaci
dosedepend
manner
figur
mice
receiv
highest
dose
afford
almost
complet
protect
p
whilst
mice
receiv
lowest
dose
suscept
mice
receiv
human
mab
irrelev
specif
though
time
death
delay
p
mice
receiv
hyperimmun
polyclon
sheep
antiserum
afford
complet
protect
data
demonstr
rel
greater
vivo
activ
consist
vitro
neutral
titer
present
tabl
better
understand
mechan
mab
confer
protect
lethal
kinet
viral
infect
passiv
immun
mice
defin
mice
passiv
immun
human
mab
irrelev
specif
challeng
h
later
level
viru
replic
differ
organ
determin
later
mice
receiv
control
mab
high
titer
viru
lung
figur
evid
extrapulmonari
dissemin
indic
viral
replic
brain
figur
spleen
figur
contrast
mice
passiv
immun
significantli
lower
titer
viru
lung
figur
p
versu
p
versu
undetect
viral
burden
brain
figur
low
titer
viru
detect
spleen
mice
receiv
figur
alongsid
reduct
lung
viral
titer
mice
receiv
prophylaxi
less
dramat
patholog
chang
pulmonari
airway
parenchym
tissu
figur
thu
percentag
abnorm
bronchiol
necrosi
viral
antigen
lung
section
mice
n
per
group
receiv
prophylaxi
less
control
mice
similarli
fewer
inflammatori
interstiti
lesion
antigen
detect
immunohistochem
stain
lung
section
mice
given
rel
control
antibodi
versu
figur
slightli
lesser
extent
prophylaxi
also
limit
bronchiol
versu
interstiti
patholog
versu
compar
control
mice
n
data
suggest
prophylaxi
probabl
confer
protect
lethal
challeng
combin
limit
viral
replic
lung
attenu
virusinduc
lung
patholog
block
extrapulmonari
dissemin
viru
distant
organ
attenu
establish
infect
repres
clinic
relev
endpoint
antivir
therapi
infect
end
efficaci
treatment
determin
balbc
mice
infect
h
previous
ld
provid
robust
protect
lethal
infect
mice
time
point
whilst
irrelev
control
mab
gave
protect
p
figur
promis
therapeut
result
clade
viru
viet
nam
led
us
examin
therapeut
efficaci
mab
antigen
diverg
viru
clade
ii
efficaci
treatment
determin
balbc
mice
infect
h
previous
ld
consist
vitro
neutral
data
tabl
mice
treat
control
mab
tabl
treatment
mab
significantli
protect
mice
p
lethal
infect
observ
neutral
vivo
suggest
factor
found
vivo
enhanc
neutral
activ
mab
account
efficaci
vivo
prevent
mortal
associ
infect
data
provid
proof
concept
mab
therapi
least
h
postinfect
mous
model
markedli
improv
surviv
highli
virul
infect
importantli
data
also
impli
possibl
obtain
signific
crossprotect
clade
ii
viru
use
mab
elicit
clade
viru
risk
devast
human
influenza
pandem
caus
influenza
strain
remain
difficult
quantifi
clear
zoonot
infect
hpai
virus
continu
occur
southeast
asia
mortal
specif
intervent
report
gener
four
fulli
human
mab
spectrum
neutral
activ
multipl
strain
hpai
virus
vitro
vivo
mab
could
potenti
adjunct
treatment
human
pandem
zoonot
case
prophylaxi
mab
lesser
extent
confer
signific
immun
mice
infect
passiv
immun
associ
significantli
reduc
viral
burden
lung
neglig
dissemin
viru
brain
spleen
viral
dissemin
might
import
aspect
pathogenesi
virus
mice
human
vietnames
patient
infect
fatal
outcom
strongli
associ
presenc
viral
genet
materi
viabl
viru
extrapulmonari
site
convers
evid
extrapulmonari
viru
dissemin
patient
surviv
addit
evid
viral
dissemin
patient
fatal
infect
high
viral
load
respiratori
tract
hypercytokinemia
multipl
organ
dysfunct
acut
respiratori
distress
syndrom
propos
model
pathogenesi
argu
earli
diagnosi
antivir
intervent
limit
ensu
inflammatori
cascad
central
treatment
although
new
strategi
antibodybas
therapi
sever
influenza
caus
virus
repres
plausibl
intervent
multipl
report
physician
use
human
blood
product
recov
influenza
patient
appear
spanish
influenza
pandem
recent
review
studi
suggest
treatment
associ
halv
mortal
earli
treatment
associ
greater
benefit
assumpt
underli
observ
neutral
antivir
antibodi
plasma
prepar
modul
cours
viral
infect
therebi
prevent
develop
acut
respiratori
distress
syndrom
complic
tenet
form
rational
therapi
use
mab
gener
studi
potenti
scaleabl
therapeut
product
free
adventiti
agent
strength
approach
human
mab
gener
describ
use
human
immun
respons
rather
anim
surrogatesth
antibodi
select
gener
respons
natur
infecti
pathogen
protect
individu
fast
screen
perform
use
function
assay
ie
neutral
allow
screen
larg
repertoir
antibodi
select
favor
profil
potenc
breadth
reactiv
sinc
antibodi
human
origin
risk
selfreact
selfantigen
minim
compar
antibodi
gener
mice
phage
display
mab
produc
studi
deriv
immort
memori
b
cell
donor
recov
infect
overal
compar
yield
neutral
b
cell
clone
previous
deriv
patient
recov
sar
coronaviru
infect
donorderiv
b
cell
clone
neutral
influenza
rel
scarc
observ
might
reflect
weak
immunogen
ha
suggest
trial
inactiv
vaccin
human
volunt
two
four
mab
characteris
studi
crossreact
antivir
activ
vitro
vivo
clade
clade
ii
virus
signific
suggest
presenc
conserv
neutral
epitop
repres
two
clade
one
mab
effect
neutral
clade
ii
viru
vivo
vitro
suggest
neutral
activ
mab
depend
upon
factor
found
vivo
complement
similar
find
previous
report
gerhard
colleagu
identifi
mous
mab
influenza
ha
neutral
activ
vivo
vitro
vitro
neutral
activ
mab
enhanc
compon
complement
system
plu
anoth
undefin
serum
factor
possibl
employ
human
mab
gener
studi
potent
therapeut
agent
least
h
infect
import
zoonot
case
human
infect
present
health
care
facil
least
sever
day
ill
onset
potenti
cocktail
crossreact
mab
could
repres
adjunct
treatment
option
infect
dose
mab
requir
effect
antiinfluenza
activ
patient
uncertain
though
note
mab
licens
use
viral
agent
respiratori
syncyti
viru
use
mgkg
bodi
weight
ongo
process
antigen
variat
antibodi
bind
site
call
antigen
drift
influenza
virus
repres
challeng
vaccin
design
also
therapi
use
mab
although
molecular
target
neutral
mab
studi
determin
presum
resid
around
highli
variabl
receptor
bind
region
differ
potenc
relat
epitop
specif
overal
avid
date
identifi
mab
epitop
escap
mutant
issu
mechan
viru
neutral
subject
ongo
virolog
crystallograph
studi
hpai
virus
continu
circul
evolv
bird
popul
certain
pandem
viru
origin
hpai
viru
resembl
virus
studi
mab
gener
neutral
activ
pandem
viru
nevertheless
encourag
broad
neutral
activ
antibodi
vitro
moder
dose
requir
vivo
confer
protect
ultim
hope
mab
other
like
could
constitut
cocktail
crossreact
neutral
antibodi
could
employ
adjunct
treatment
influenza
background
everi
year
million
peopl
catch
influenza
viral
diseas
nose
throat
airway
although
recov
influenza
outbreak
epidem
kill
half
million
peopl
annual
epidem
occur
small
frequent
chang
viral
protein
antigen
immun
system
respond
mean
immun
respons
produc
one
year
provid
partial
protect
influenza
next
year
human
flu
virus
also
occasion
appear
contain
major
antigen
chang
peopl
littl
immun
virus
often
origin
anim
bird
virus
start
deadli
pandemicsglob
epidem
spanish
flu
pandem
asian
flu
hong
kong
flu
kill
million
expert
believ
anoth
pandem
overdu
may
trigger
avian
influenza
virusth
name
indic
bird
viru
carri
type
hemagglutinin
type
neuraminidas
two
major
flu
antigen
rapidli
kill
infect
bird
present
flock
around
world
sinc
caus
case
human
flu
death
peopl
caught
close
contact
infect
bird
luckili
rare
pass
peopl
studi
done
might
acquir
abil
move
peopl
start
human
influenza
pandem
time
virus
resist
antivir
drug
use
treat
flu
inevit
lag
month
emerg
human
pandem
strain
bulk
product
vaccin
effect
thu
new
prevent
therapeut
strategi
need
combat
human
infect
one
possibl
passiv
immunotherapytr
peopl
antibodi
protein
recogn
antigen
stop
infect
cell
socal
neutral
antibodi
studi
research
gener
neutral
human
monoclon
antibodi
laboratoryproduc
prepar
contain
one
type
human
antibodi
test
abil
halt
viral
growth
mice
infect
research
find
patient
surviv
infect
make
neutral
antibodi
research
isol
immort
immun
cell
make
antibodi
patient
blood
grew
cell
separ
purifi
antibodi
cell
made
monoclon
antibodi
test
abil
neutral
flu
virus
laboratori
research
identifi
sever
neutral
strain
patient
origin
infect
chose
two
studi
test
tube
four
antibodi
neutral
close
relat
virus
viru
differ
lineag
clade
also
caus
human
diseas
addit
origin
viru
although
differ
efficaci
mice
antibodi
provid
protect
infect
origin
viru
given
day
one
three
day
infect
three
antibodi
also
partli
protect
mice
differ
clade
final
research
show
antibodi
protect
mice
limit
viral
replic
lessen
deleteri
effect
viru
lung
stop
viral
spread
lung
find
mean
result
indic
passiv
immunotherapi
human
monoclon
antibodi
could
help
combat
avian
start
human
pandem
passiv
immunotherapi
alreadi
use
prevent
infect
sever
virus
addit
crude
form
approachearli
treatment
patient
plasma
liquid
portion
blood
convalesc
patientshalv
death
rate
spanish
flu
pandem
larg
amount
pure
monoclon
antibodi
rel
easili
made
clinic
use
studi
indic
monoclon
antibodi
neutral
virus
differ
clade
research
sound
note
caution
howev
passiv
immunotherapi
help
halt
pandem
warn
monoclon
antibodi
test
see
whether
neutral
current
circul
virus
also
emerg
pandem
version
might
antigen
distinct
addit
inform
pleas
access
web
site
via
onlin
version
summari
http
includ
key
fact
avian
influenza
us
nation
institut
allergi
infecti
diseas
featur
season
avian
pandem
flu
world
health
organ
factsheet
influenza
inform
avian
influenza
includ
latest
figur
confirm
human
case
uk
health
protect
agenc
inform
season
avian
pandem
influenza
wikipedia
page
passiv
immun
monoclon
antibodi
note
wikipedia
onlin
encyclopedia
anyon
edit
